High dose intravenous steroid therapy for severe posterior segment uveitis in Behçet's disease

Br J Ophthalmol. 2002 May;86(5):521-3. doi: 10.1136/bjo.86.5.521.

Abstract

Aim: To evaluate the safety and effectiveness of high dose intravenous steroid therapy (HDIST) in Behçet's disease patients with severe posterior segment uveitis attacks.

Methods: Five patients with ocular Behçet's disease were treated with HDIST for severe posterior segment attacks. Two patients had vasculitis, one patient had papillitis, and the other two had retinitis; four patients also had accompanying severe vitritis. The visual acuities and improvement in ocular signs after HDIST were evaluated.

Results: During HDIST, patients had no systemic complications caused by treatment. All patients responded to HDIST with evidence of a decrease in intraocular inflammatory activity and improved visual acuities within a mean time of 7 (1-15) days of commencing treatment. During follow up three out of five patients had new posterior segment attacks.

Conclusion: HDIST is effective in controlling severe, vision threatening acute posterior segment Behçet's uveitis attacks and in improving visual function in a short period of time

Publication types

  • Case Reports

MeSH terms

  • Administration, Oral
  • Adolescent
  • Adult
  • Anti-Inflammatory Agents / administration & dosage*
  • Behcet Syndrome / complications*
  • Female
  • Humans
  • Infusions, Intravenous
  • Male
  • Methylprednisolone / administration & dosage*
  • Middle Aged
  • Treatment Outcome
  • Uveitis, Posterior / drug therapy*
  • Uveitis, Posterior / etiology

Substances

  • Anti-Inflammatory Agents
  • Methylprednisolone